Warnings, Columns-Drugs & Supplements, October 2005
September 26, 2005
Bristol-Myers Squibb and ImClone Systems Update Erbitux Warnings NEW YORK - Bristol-Myers Squibb Co. and ImClone Systems Inc. recently announced updated warnings for their colorectal cancer drug Erbitux (cetuximab) to reflect increased concerns over patients' adverse reactions. The precautions and adverse reactions sections now include information regarding an increased incidence of hypomagnesemia seen in clinical trials and recommendations for electrolyte monitoring, the companies said in a Sept. 13 letter to the Food and Drug Administration. The companies said the warnings and dosage and administration sections also include a recommendation that healthcare providers observe patients for …
UPCOMING CONFERENCES
HarrisMartin’s Artificial Stone Silicosis Epidemic Litigation ConferenceJanuary 10, 2025 - Long Beach, CA
The Westin Long Beach
|
